Orchestra BioMed Holdings, Inc.
NASDAQOBIO enters the week after its most active news session in months — a Q1 earnings beat, a fresh BACKBEAT trial update, and a Barclays target raise all landing within hours of each other. The catalyst was Tuesday's Q1 print. Orchestra BioMed reported EPS of -$0.33, beating the -$0.41 consensus estimate by $0.07. Revenue of $110K missed the $190K estimate — a thin figure that…
Snapshot as of 28 Jun 2026
OBIO enters the week after its most active news session in months — a Q1 earnings beat, a fresh BACKBEAT trial update, and a Barclays target raise all landing within hours of each other. The catalyst was Tuesday's Q1…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for OBIO — free to start on ORTEX.
Sign up for free →Open OBIO on ORTEX